21 小时
GlobalData on MSNActuate sees 37% cut in risk of death in Phase II pancreatic cancer trialThe trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...
Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year ...
Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...
Marker Therapeutics (NASDAQ:MRKR) shares popped 11% Tuesday morning after the immuno-oncology company won a $9.5M grant from ...
Cancer is one of the most formidable health challenges of our time, affecting nearly half of us during our lives. While treatments have significantly improved in recent decades, the biggest challenge ...
Dec. 12, 2024 — Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular ...
Pulmonary metastases occur also very often in sarcoma, a relatively rare type of cancer. As many as 20% of soft tissue sarcomas and up to 40% of bone sarcomas develop lung metastases. Occasionally, ...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...
Caregivers are crucial in the pancreatic cancer patient’s journey. We have information and resources to guide you as you care for a loved one facing the disease.
IMM-1-104 is a small molecule commercialized by Immuneering, with a leading Phase II program in Pancreatic Cancer.
Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of ...
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果